Baird's Investment Banking Group is pleased to announce the following transaction:

September 2021
Leap Therapeutics, Inc.
Follow-on Offering
Baird served as lead manager on this offering
$104.000 Million

Leap Therapeutics, Inc. (“Leap”) (NASDAQ-GM:LPTX) recently completed an upsized underwritten public offering of 27,568,072 shares of its common stock at a public offering price per share of $2.85 and pre-funded warrants to purchase 8,771,928 shares of its common stock at a purchase price per warrant of $2.849. The offering included the exercise in full by the underwriters of their option to purchase an additional 4,740,000 shares of common stock at the public offering price per share. The gross proceeds to Leap from the offering were approximately $104 million.

Leap is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

For additional information about this transaction, please contact:

Derrick Li +1-646-557-2333
Lance Lange +1-414-765-7079
Michael Kim +1-312-609-4482
Matt Gailey +1-414-765-1458